Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380941 | 0.77 | LMNA (0.48) | CNR1LMNATP53 | |
| SCHEMBL5410217 | 0.75 | CNR1 (0.48) | HRH4CNR1CHRNB2CHRNA4 | |
| SCHEMBL5410210 | 0.75 | CNR1 (0.48) | HRH4CNR1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL5405780 | 0.75 | CNR1 (0.48) | HRH4CNR1 | |
| Hydrochloric Acid SCHEMBL5405784 | 0.75 | CNR1 (0.48) | HRH4CNR1 | |
| SCHEMBL5370878 | 0.74 | CNR1 (0.47) | CNR1LMNATP53 | |
| SCHEMBL5379203 | 0.71 | CNR1 (0.41) | CNR1LMNATP53 | |
| SCHEMBL5368810 | 0.71 | CNR1 (0.41) | CNR1LMNATP53 | |
| SCHEMBL27636216 | 0.71 | ADORA3 (0.38) | CNR1LMNATP53 | |
| SCHEMBL27636190 | 0.69 | CNR1 (0.40) | CNR1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | claimed |
| US-20040248881-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-09 | — | — | US | claimed |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| EP-1636233-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108728-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248881-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248881-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CSNK1E 509/4885HRH4 223/4885CNR1 1/4885 |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR2, CNR1, GPR18 | CSNK1E 553/4885HRH4 207/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.